XPO1 mutations were reported to be significantly overrepresented in a relapsed/refractory DLBCL patient cohort and in patients with mediastinal large B-cell lymphoma [20, 32]. This evidence concerns the gene XPO1 and diffuse large B-cell lymphoma.